City banks nearly $100M for next-gen RNAi drugs

City banks nearly $100M for next-gen RNAi drugs

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

City Therapeutics Raises $99.5 Million Series B to Advance RNAi Pipeline and Platform

City Therapeutics has completed a $99.5 million Series B financing, securing support from new investors Viking Global Investors and Sofinnova Investments, alongside a syndicate of existing and new backers. The financing included participation from Casdin Capital, NYBC Ventures, ARCH Venture Partners, Fidelity Management & Research Company, Invus, Slate Path Capital, Rock Springs Capital, Regeneron Ventures, AN Ventures, and other undisclosed inv…

City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 8, 2026-

City Therapeutics gets $99M to gather data on three RNAi medicines

City Therapeutics, the next-gen RNAi startup founded and led by former Alnylam executives, has collected $99.5 million to fund the clinical development of its first three candidates and expand into targets beyond the liver. The ...